Orthopädie & Rheuma

, Volume 16, Issue 6, pp 30–36

Gicht ist mehr als nur Podagra

Diagnose, Prävention und Therapie der Stoffwechselkrankheit
  • Dieter Schöffel

Bei rechtzeitiger Diagnose und adäquater Therapie hat die Gicht eine exzellente Prognose. Wenn auch der zugrunde liegende Stoffwechseldefekt nicht beseitigt werden kann, so gilt diese häufige Erkrankung dennoch als „heilbar“. Die meisten artikulären und extraartikulären Manifestationen können durch eine dauerhafte Normalisierung der Harnsäure therapiert werden.


  1. 1.
    Ahern MJ, Reid C, Gordon TP, McCredie M, Brooks PM, Jones M. Does colchicine work? The results of the first controlled study in acute gout. Aust NZ J Med 1987; 17: 301–4CrossRefGoogle Scholar
  2. 2.
    Andrés M, Pascual E. Anakinra for a refractory case of intermittent hydrarthrosis with a TRAPS-related gene mutation. Ann Rheum Dis 2013; 72: 155PubMedCrossRefGoogle Scholar
  3. 3.
    Baker JF, Synnott KA. Clinical images: gout revealed on arthroscopy after minor injury. Arthritis Rheum 2010; 62: 895PubMedCrossRefGoogle Scholar
  4. 4.
    Becker MA, Schumacher HR, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353: 2450–61PubMedCrossRefGoogle Scholar
  5. 5.
    Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004; 31: 2429–32PubMedGoogle Scholar
  6. 6.
    Brauer GW, Prior IA. A prospective study of gout in New Zealand Maoris. Ann Rheum Dis 1978; 37: 466–72PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 1987; 82: 421–6PubMedCrossRefGoogle Scholar
  8. 8.
    Chen SY, Chen CL, Shen ML: Severity of gouty arthritis is associated with q-wave myocardial infarction: a large-scale, cross-sectional study. Clin Rheumatol 2007; 26: 308–13PubMedCrossRefGoogle Scholar
  9. 9.
    Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004; 363: 1277–81PubMedCrossRefGoogle Scholar
  10. 10.
    Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, daily and protein intake, and the risk of gout in men. N Engl J Med 2004; 350: 1093–103PubMedCrossRefGoogle Scholar
  11. 11.
    Choi HK, Curhan G. „Coffee, tea, and caffeine consumption and serum uric acid level: the third national health and nutrition examination survey“. Arthritis Rheum 2007; 57: 816–21PubMedCrossRefGoogle Scholar
  12. 12.
    Choi HK, Gao X, Curhan G. Vitamin C intake and the risk of gout in men: a prospective study. Arch. Intern. Med. 2009; 169: 502–7PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart Disease. Circulation 2007; 116: 894–900PubMedCrossRefGoogle Scholar
  14. 14.
    Choi HK, Al-Arfaj A, Eftekhari A et al. Dual energy computed tomography in tophaceous gout. Ann Rheum Dis 2009; 68: 1609–12PubMedCrossRefGoogle Scholar
  15. 15.
    Dalbeth N, Pool B, Gamble GD et al. Cellular characterization of the gouty tophus. Arthrits Rheum 2010; 62: 1549–56CrossRefGoogle Scholar
  16. 16.
    De Vera MA, Mushfiqur Rahman M, Bhole V. The Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study. Ann Rheum Dis 2010; 69: 1162–64PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Eggebeen AT. Gout: an update. Am Fam Physician 2007; 76: 801–8PubMedGoogle Scholar
  18. 18.
    Fernandez C, Noguera R, Gonzalez JA, Pascual E. Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide. J Rheumatol 1999; 26: 2285–6PubMedGoogle Scholar
  19. 19.
    Gibson T, Simmonds HA, Potter C, Rogers V. A controlled study of the effect of long term allopurinol treatment on renal function in gout. Adv Exp Med Biol 1980; 122A: 257–62PubMedCrossRefGoogle Scholar
  20. 20.
    Janssens HJ, Janssen M, van de Lisdonk EH, van Riel PL, {van} Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 2008; 371: 1854–60PubMedCrossRefGoogle Scholar
  21. 21.
    Khanna D, Fitzgerald J, Khanna PP. 2012 American College of Rheumatology Guidelines for Management of Gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia: Arthritis Care Res 2012; 64: 1431–46CrossRefGoogle Scholar
  22. 22.
    Krishnan E, Svendsen K, Neaton JD et al. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 2008; 168: 1104–10PubMedCrossRefGoogle Scholar
  23. 23.
    Logan JA, Morrison E, McGill PE. Serum uric acid in acute gout. Ann Rheum Dis 1997; 56: 696–7PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Pascual E. Persistence of monosodium urate crystals, and low grade inflammation, in the synovial fluid of untreated gout. Arthritis Rheum 1991; 34: 141–45PubMedCrossRefGoogle Scholar
  25. 25.
    Pascual E, Castellano J A. Treatment with colchicine decreases the white cell counts in the synovial fluid of asymptomatic knees which contain monosodium urate crystals. J Rheumatol 1992; 19: 600–3PubMedGoogle Scholar
  26. 26.
    Pascual E, Martínez A, Ordóñez S. Gout: the mechanism of urate crystal nucleation and growth. A hypothesis based in facts. Joint Bone Spine 2013; 80: 1–4PubMedCrossRefGoogle Scholar
  27. 27.
    Richette P, Bardin T. Gout. Lancet 2010; 375: 318–28PubMedCrossRefGoogle Scholar
  28. 28.
    Richette P, Bardin T. Should prednisolone be first-line therapy for acute gout? Lancet 2008; 372: 1301PubMedCrossRefGoogle Scholar
  29. 29.
    Rigby AS, Wood PH. Serum uric acid levels and gout: what does this herald for the population? Clin Exp Rheumatol 1994; 12: 395–400PubMedGoogle Scholar
  30. 30.
    Roddy E, Zhang W, Doherty M. Are joints affected by gout also affected by osteoarthritis? Ann Rheum Dis. 2007; 66: 1374–77Google Scholar
  31. 31.
    Rouault T, Caldwell DS, Holmes EW. Aspiration of the asymptomatic metatarsophalangeal joint in gout patients and hyperuricemic controls. Arthritis Rheum 1982; 25: 209–12PubMedCrossRefGoogle Scholar
  32. 32.
    Roubenoff R, Klag MJ, Mead LA, Liang KY, Seidler AJ, Hochberg MC. Incidence and risk factors for gout in white men. JAMA 1991; 266: 3004–7PubMedCrossRefGoogle Scholar
  33. 33.
    Rubin BR, Burton R, Navarra S, Antigua J, Londono J, Pryhuber KG, et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum 2004; 50: 598–606PubMedCrossRefGoogle Scholar
  34. 34.
    Rundles RW, Metz EN, Silberman HR. Allopurinol in the treatment of gout. Ann Intern Med 1966; 64: 229–58PubMedCrossRefGoogle Scholar
  35. 35.
    Schlesinger N. Diagnosing and treating gout: a review to aid primary care physicians. Postgrad Med 2010; 122: 157–61PubMedCrossRefGoogle Scholar
  36. 36.
    Segal JB, Albert D. Diagnosis of crystal-induced arthritis by synovial fluid examination for crystals: lessons from an imperfect test. Arthritis Care Res 1999; 12: 376–80PubMedCrossRefGoogle Scholar
  37. 37.
    Swan A, Amer H, Dieppe P. The value of synovial fluid assays in the diagnosis of joint disease: a literature survey. Ann Rheum Dis 2002; 61: 493–8PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Taylor CT, Brooks NC, Kelley KW. Corticotropin for acute management of gout. Ann Pharmacother 2001; 35: 365–8PubMedCrossRefGoogle Scholar
  39. 39.
    Templeton JS. Azapropazone or allopurinol in the treatment of chronic gout and/or hyperuricaemia. A preliminary report. Br J Clin Pract 1982; 36: 353–8PubMedGoogle Scholar
  40. 40.
    Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol 2010; 6: 30–8PubMedCrossRefGoogle Scholar
  41. 41.
    Vandenberg MK, Moxley G, Breitbach SA, Roberts WN. Gout attacks in chronic alcoholics occur at lower serum urate levels than in nonalcoholics. J Rheumatol 1994; 21: 700–4PubMedGoogle Scholar
  42. 42.
    Vazquez-Mellado J, Cuan A, Magana M, Pineda C, Cazarin J, Pacheco-Tena C, et al. Intradermal tophi in gout: a case-control study. J Rheumatol 1999; 26: 136–40PubMedGoogle Scholar
  43. 43.
    Vogt B. Urate oxidase (rasburicase) for treatment of severe tophaceous gout. Nephrol Dial Transplant 2005; 20: 431–33PubMedCrossRefGoogle Scholar
  44. 44.
    Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977; 20: 895–900PubMedCrossRefGoogle Scholar
  45. 45.
    Wei L, Mackenzie IS, Yang Chen Y, Allan D Struthers AD, MacDonald TM. Impact of allopurinol use on urate concentration and cardiovascular outcome. Br J Clin Pharmacol 2011; 71: 600–7PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    Werlen D, Gabay C, Vischer TL. Corticosteroid therapy for the treatment of acute attacks of crystal-induced arthritis: an effective alternative to nonsteroidal antiinflammatory drugs. Rev Rhum (Engl Ed) 1996; 63: 248–54Google Scholar
  47. 47.
    Winzenberg T, Buchbinder R. Cochrane Musculoskeletal Group review: acute gout. Steroids or NSAIDs? Let this overview from the Cochrane Group help you decide what‘s best for your patient. J Fam Pract 2009; 58: E1–4PubMedGoogle Scholar
  48. 48.
    Wurzner G, Gerster JC, Chiolero A, Maillard M, Fallab-Stubi CL, Brunner HR, et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 2001; 19: 1855–60PubMedCrossRefGoogle Scholar
  49. 49.
    Yamanaka H, Togashi R, Hakoda M, Terai C, Kashiwazaki S, Dan T, et al. Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment. Adv Exp Med Biol 1998; 431: 13–8PubMedCrossRefGoogle Scholar
  50. 50.
    Yu TF. The effect of allopurinol in primary and secondary gout. Arthritis Rheum 1965; 8: 905–6PubMedCrossRefGoogle Scholar
  51. 51.
    Zhang W, Doherty M, Pascual E et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1301–13PubMedCentralPubMedCrossRefGoogle Scholar
  52. 52.
    Zhang W, Doherty M, Bardin T et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1312–24PubMedCentralPubMedCrossRefGoogle Scholar
  53. 53.
    Zhang Y, Neogi T, Chen C, Chaisson C, Hunter DJ, Choi HK. Cherry consumption and decreased risk of recurrent gout attacks. Arthritis Rheum 2012;64: 4004–11PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Urban & Vogel 2013

Authors and Affiliations

  • Dieter Schöffel
    • 1
  1. 1.Ostelogisches ZentrumMannheimDeutschland

Personalised recommendations